Skip to main content
. 2012 Apr 23;2012:901956. doi: 10.1155/2012/901956

Table 2.

Overall survival in months of patients receiving platinum-based chemotherapy (1) or not (0), with respect to their eIF3a expression status.

eIF3a expression
Low High
Platinum-based
chemotherapy
Average overall survival (months)

1 67.2 27.9
0 53.3 35.7